Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 28, 2009

View Archived Issues

SUVN-911 exhibits safety and shows antidepressant properties in vivo

BAP and PINP identified as bone metabolism biomarkers for monitoring radionuclide cancer therapy

ARC-1779 exhibits antithrombotic activity in an ex vivo model

CURRENT-OASIS 7 trial to assess optimal clopidogrel and aspirin doses in ACS

No effect of fondaparinux on left ventribular function in STEMI

GSK reports preliminary results from clinical trial of Pandemrix H1N1 vaccine in children

FDA grants accelerated approval to GSK and Genmab's Arzerra antibody in CLL

Icagen reports results from phase IIa exercise-induced asthma study of senicapoc

Patient-reported outcome results of phase III tesamorelin trials reported by Theratechnologies

Living Cell Technologies reports results from phase I/IIa clinical trial of DiabeCell

Novartis reports results from third quarter of 2009

Intercept presents results from phase II study of INT-747 in primary biliary cirrhosis

Avineuro reports phase I clinical trial results for AVN-101

MC5 receptor antagonists claimed by Mimetica for the treatment of acne

Boehringer Ingelheim describes 11beta-HSD-1 inhibitors for the treatment of diabetes

Schering-Plough presents ERK inhibitors for the treatment of cancer

Hyperion Therapeutics enrolls first patient in pivotal trial of HPN-100 in urea cycle disorders

Celsion and Yakult treat first HCC patient in Japan in global phase III ThermoDox trial

NeoPharm submits application for phase II LE-DT study in pancreatic cancer

Anti-IL-17 antibody LY-2439821 improves signs and symptoms of RA

ZymoGenetics starts phase II PEG-Interferon lambda trial in hepatitis C

Astellas and Medivation sign global agreement for MDV-3100 in prostate cancer

PolyMedix completes phase Ib clinical trial of heparin antagonist PMX-60056

GlaxoSmithKline and Theravance commence phase III program for COPD

CTG Pharma claims novel ophthalmic drugs for the treatment of glaucoma